Drugs / ivlv-X1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03217617 | Jun 2024 → Dec 2026 expected | combined immunodeficiency, X-linked | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ivlv-X1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03217617 ↗ |
| Action | Restore | “functionally correct the genetic defect” NCT03217617 ↗ |
| Route | Intravenous | “direct intravenous (iv) injection” NCT03217617 ↗ |